Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study

AIMS: The understanding of second‐line use of glucose‐lowering drugs (GLDs) in the general population with type 2 diabetes (T2D) treatment is important as recent results have shown cardiovascular benefits with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) and glucagon‐like peptide‐1 receptor a...

詳細記述

保存先:
書誌詳細
出版年:Endocrinol Diabetes Metab
主要な著者: Persson, Frederik, Bodegard, Johan, Lahtela, Jorma T., Nyström, Thomas, Jørgensen, Marit E., Jensen, Majken Linneman, Gulseth, Hanne L., Thuresson, Marcus, Hoti, Fabian, Nathanson, David, Norhammar, Anna, Birkeland, Kåre I., Eriksson, Johan G., Eriksson, Jan W.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2018
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6354817/
https://ncbi.nlm.nih.gov/pubmed/30815564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.36
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料